Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis
Author:
Affiliation:
1. Leukemia Service, Department of Medicine,
2. Department of Epidemiology and Biostatistics, and
3. Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/129/13/1878/1399428/blood749507.pdf
Reference25 articles.
1. Childhood acute lymphoblastic leukemia: Progress through collaboration;Pui;J Clin Oncol,2015
2. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia;DeAngelo;Leukemia,2015
3. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study;Huguet;J Clin Oncol,2009
4. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia;Douer;J Clin Oncol,2014
5. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia;O’Brien;Cancer,2008
Cited by 77 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome–Negative B-Precursor ALL;Journal of Clinical Oncology;2024-01-20
2. Leveraging CD19CAR T cells early in the treatment of older patients with B-ALL: are we there yet?;Leukemia & Lymphoma;2024-01-05
3. SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-01
4. Temporal changes in survival among adult patients with acute lymphoblastic leukemia diagnosed in the period 1998-2020 – A Danish nationwide population-based study;2023-12-14
5. Combination of the biomarkers for aging and cancer? - Challenges and current status;Translational Oncology;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3